-transparent.png){kind=logo}
In Taiwan, the prevalence of circulating anti-HCV is 2 percent among first-time voluntary Chinese blood donors, 10 percent among donors with elevated ALT levels (greater than 45 IU/L), and higher among older men. The carrier rate for HBsAg was 18.6 percent and the frequency of positive HBV marker(s) (HBsAg, anti-HBc, anti-HBs) was 86.4 percent among first-time donors. There is no significant correlation between HBV and HCV infections in Taiwan, because there is no significant difference in the frequency of anti-HCV among donors with or without HBV markers. The frequency of anti-HCV among qualified donors in Taiwan (ALT less than 45 IU/L, not tested for anti-HBc) is 1.8 percent, which is not significantly different from the frequency (1.6%) in donors with normal ALT and negative for HBV marker(s) (qualified donors by Western Standards). Therefore, ALT is the most important surrogate marker for HCV infection in Taiwan.
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
February 1991,
Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
October 2005,
Hematology (Amsterdam, Netherlands),
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
January 1998,
Annals of Saudi medicine,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
November 1994,
Medicina clinica,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
September 1991,
Annals of Saudi medicine,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
March 1997,
Annals of hematology,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
October 1992,
Medicina clinica,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
June 2007,
Transfusion medicine (Oxford, England),
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
February 1991,
Nihon rinsho. Japanese journal of clinical medicine,
M Lin-Chu, and
S J Tsai, and
J Watanabe, and
K Nishioka
February 2009,
Virology journal,
